{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IVT+Aflibercept", "query": { "intervention": "IVT Aflibercept" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 64, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IVT+Aflibercept&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-13T01:31:29.739Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06116916", "title": "Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetic Macular Edema (DME)" ], "interventions": [ { "name": "KHK4951", "type": "DRUG" }, { "name": "Aflibercept Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyowa Kirin Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2024-01-09", "completion_date": "2026-09-30", "has_results": false, "last_update_posted_date": "2025-10-30", "last_synced_at": "2026-09-13T01:31:29.739Z", "location_count": 40, "location_summary": "Mesa, Arizona • Tucson, Arizona • Arcadia, California + 36 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Arcadia", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Encino", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06116916" }, { "nct_id": "NCT04418427", "title": "ADVM-022 Intravitreal Gene Therapy for DME", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetic Macular Edema", "Diabetic Retinopathy" ], "interventions": [ { "name": "6E11 vg/eye of ADVM-022", "type": "BIOLOGICAL" }, { "name": "2E11 vg/eye of ADVM-022", "type": "BIOLOGICAL" }, { "name": "Aflibercept", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Adverum Biotechnologies, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2020-05-28", "completion_date": "2023-06-14", "has_results": true, "last_update_posted_date": "2025-07-10", "last_synced_at": "2026-09-13T01:31:29.739Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Golden", "state": "Colorado" }, { "city": "Deerfield Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04418427" }, { "nct_id": "NCT00509795", "title": "Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Macular Degeneration" ], "interventions": [ { "name": "ranibizumab", "type": "BIOLOGICAL" }, { "name": "aflibercept injection (VEGF Trap-Eye, BAY86-5321)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 1217, "start_date": "2007-08", "completion_date": "2011-07", "has_results": true, "last_update_posted_date": "2012-12-28", "last_synced_at": "2026-09-13T01:31:29.739Z", "location_count": 176, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 144 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00509795" }, { "nct_id": "NCT03710564", "title": "Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Age-Related Macular Degeneration" ], "interventions": [ { "name": "Brolucizumab", "type": "BIOLOGICAL" }, { "name": "Aflibercept", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 535, "start_date": "2018-10-30", "completion_date": "2021-07-01", "has_results": true, "last_update_posted_date": "2023-01-30", "last_synced_at": "2026-09-13T01:31:29.739Z", "location_count": 60, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Huntington Beach, California + 51 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Huntington Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03710564" }, { "nct_id": "NCT05769153", "title": "Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neovascular Age-related Macular Degeneration (nAMD)" ], "interventions": [ { "name": "AR-14034 SR implant lower dose", "type": "DRUG" }, { "name": "AR-14034 SR implant higher dose", "type": "DRUG" }, { "name": "AR-14034 SR implant", "type": "DRUG" }, { "name": "Aflibercept Injection", "type": "DRUG" }, { "name": "Sham procedure", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alcon Research", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 139, "start_date": "2023-12-06", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-09-13T01:31:29.739Z", "location_count": 42, "location_summary": "Dothan, Alabama • Gilbert, Arizona • Phoenix, Arizona + 37 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Encino", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05769153" }, { "nct_id": "NCT03126786", "title": "Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "IVT aflibercept", "type": "DRUG" }, { "name": "Sham SC", "type": "DRUG" }, { "name": "SC CLS-TA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Clearside Biomedical, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 71, "start_date": "2017-07-11", "completion_date": "2018-04-17", "has_results": true, "last_update_posted_date": "2021-05-13", "last_synced_at": "2026-09-13T01:31:29.739Z", "location_count": 29, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 25 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Mountain View", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03126786" }, { "nct_id": "NCT06116890", "title": "Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neovascular Age-Related Macular Degeneration (nAMD)" ], "interventions": [ { "name": "KHK4951", "type": "DRUG" }, { "name": "Aflibercept Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyowa Kirin Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 180, "start_date": "2024-01-31", "completion_date": "2026-09-30", "has_results": false, "last_update_posted_date": "2025-10-30", "last_synced_at": "2026-09-13T01:31:29.739Z", "location_count": 38, "location_summary": "Mesa, Arizona • Tucson, Arizona • Arcadia, California + 34 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Arcadia", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Encino", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06116890" }, { "nct_id": "NCT07064759", "title": "Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neovascular Age-Related Macular Degeneration (nAMD)" ], "interventions": [ { "name": "4D-150 IVT (3E10 vg/eye)", "type": "BIOLOGICAL" }, { "name": "EYLEA® (aflibercept) Injection 2 mg (0.05mL)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "4D Molecular Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 480, "start_date": "2025-07-22", "completion_date": "2029-02", "has_results": false, "last_update_posted_date": "2026-04-16", "last_synced_at": "2026-09-13T01:31:29.739Z", "location_count": 54, "location_summary": "Scottsdale, Arizona • Sun City, Arizona • Tucson, Arizona + 49 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Campbell", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07064759" }, { "nct_id": "NCT06470373", "title": "A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neovascular Age-related Macular Degeneration (nAMD)" ], "interventions": [ { "name": "RBS-001 Solution for intravitreal injection", "type": "DRUG" }, { "name": "Eylea® Solution for intravitreal injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rophibio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 434, "start_date": "2025-07", "completion_date": "2026-09", "has_results": false, "last_update_posted_date": "2025-04-06", "last_synced_at": "2026-09-13T01:31:29.739Z", "location_count": 7, "location_summary": "Phoenix, Arizona • Springdale, Arkansas • Erie, Pennsylvania + 3 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Erie", "state": "Pennsylvania" }, { "city": "Germantown", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06470373" }, { "nct_id": "NCT07496567", "title": "A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Macular Degeneration", "Age-Related Macular Degeneration", "Choroidal Neovascularization", "Wet Macular Degeneration" ], "interventions": [ { "name": "Tiespectus", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EyeBiotech Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 960, "start_date": "2026-04-15", "completion_date": "2028-07-31", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-09-13T01:31:29.739Z", "location_count": 52, "location_summary": "Gilbert, Arizona • Encino, California • Mountain View, California + 49 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Encino", "state": "California" }, { "city": "Mountain View", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07496567" } ] }